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AbstrACt
Objective To investigate delays from symptom onset to 
rheumatology assessment for patients with a new onset of 
rheumatoid arthritis (RA) or unclassified arthritis.
Methods Newly presenting adults with either RA or 
unclassified arthritis were recruited from rheumatology 
clinics. Data on the length of time between symptom 
onset and first seeing a GP (patient delay), between first 
seeing a general practitioner (GP) and being referred to a 
rheumatologist (general practitioner delay) and being seen 
by a rheumatologist following referral (hospital delay) were 
captured.
results 822 patients participated (563 female, mean age 
55 years). The median time between symptom onset and 
seeing a rheumatologist was 27.2 weeks (IQR 14.1–66 
weeks); only 20% of patients were seen within the first 
3 months following symptom onset. The median patient 
delay was 5.4 weeks (IQR 1.4–26.3 weeks). Patients who 
purchased over-the-counter medications or used ice/heat 
packs took longer to seek help than those who did not. In 
addition, those with a palindromic or an insidious symptom 
onset delayed for longer than those with a non-palindromic 
or acute onset. The median general practitioner delay was 
6.9 weeks (IQR 2.3–20.3 weeks). Patients made a mean 
of 4 GP visits before being referred. The median hospital 
delay was 4.7 weeks (IQR 2.9–7.5 weeks).
Conclusion This study identified delays at all levels in 
the pathway towards assessment by a rheumatologist. 
However, delays in primary care were particularly long. 
Patient delay was driven by the nature of symptom onset. 
Complex multi-faceted interventions to promote rapid 
help seeking and to facilitate prompt onward referral from 
primary care should be developed.
IntrOduCtIOn  
Rheumatoid arthritis (RA) is a chronic 
inflammatory disease affecting approxi-
mately 1% of the population.1 2 RA is associ-
ated with significant morbidity in large part 
as a consequence of extra-articular comor-
bidities associated with systemic inflamma-
tion. In the UK, it has been estimated that 
RA costs the National Health Service (NHS) 
around £560 million per year and that addi-
tional costs to the economy of sick leave and 
work-related disability total £1.8 billion per 
year.3 The first 3 months following the onset 
of RA symptoms represents an important 
therapeutic window.4 Treatment during this 
phase improves long-term clinical outcomes, 
increasing the proportion of patients whose 
disease enters remission, reducing RA 
related joint damage and reducing the even-
tual need for joint replacement surgery.5–10 
Therefore, it is vital that patients are seen by 
rheumatologists rapidly following the onset 
of RA symptoms to allow the rapid intro-
duction of disease-modifying anti-rheumatic 
drug (DMARD) treatment. However, despite 
increased recognition of the benefits of early 
treatment there remains considerable delay 
between symptom onset and the initiation 
of therapy.11–13 Indeed a report by the UK’s 
strengths and limitations of this study
 ► A key strength of this study is that it surveyed a 
large sample of patients with new onset rheumatoid 
arthritis.
 ► Participants were recruited from multiple National 
Health Service Trusts in the UK to identify delays in 
access to care.
 ► Data on delay timepoints, demographic character-
istics and consultation behaviour were gathered 
from multiple sources including patient self-report, 
healthcare professionals assessment and referral 
letters.
 ► Limitations include the fact that data were collected 
at the point of diagnosis and information regarding 
key dates (in particular the onset of symptoms and 
presentation to primary care) were reliant on patient 
recall.
 ► An additional limitation was that the interval be-
tween first consultation with a rheumatologist and 
initiation of treatment was not measured.
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National Audit Office (NAO) in 2009 estimated that only 
10% of patients with RA were treated within 3 months of 
symptom onset. The NAO’s modelling suggested signif-
icant financial benefits for the broader economy and 
quality of life benefits for the individual if the proportion 
of patients treated earlier was increased.3 
The patient’s pathway to care can be delayed for a 
number of reasons, including delays on the part of the 
patient in recognising the significance of the early symp-
toms of RA.14–16 Recent research has linked patients’ 
perceptions of RA and coping styles to the length of 
time taken to seek help.17 Before seeking medical help 
from a physician, patients may seek help from a range 
of services including complementary therapists, pharma-
cists and telephone and online services. However, the use 
of these services at the onset of inflammatory arthritis has 
not been fully explored. Primary healthcare professionals 
often find the early symptoms of RA difficult to distin-
guish from those of other rheumatic diseases, making 
timely and appropriate referrals to rheumatologists 
challenging.18 19 There may thus be delays in healthcare 
professionals making a referral to a rheumatologist and 
also in assessment at the secondary care level, contrib-
uting further to the delay in making a diagnosis and 
commencing appropriate therapy.
Several studies conducted across a range of countries 
have shown long delays between the onset of symptoms 
and a patient’s first consultation with a rheumatolo-
gist.20–23 However, data related to lengths of time between 
the onset of inflammatory musculoskeletal symptoms 
and first seeing a GP, between first seeing a GP and being 
referred to a rheumatologist and being seen by a rheu-
matologist following referral were not available across 
multiple NHS Trusts in multiple regions of the UK at the 
time of this study.
AIM
The aim of this study was to investigate the extents of 
delay in assessment of patients with RA and unclassified 
arthritis. Specifically the study assessed extents of delay at 
the level of the patient in seeking help from the general 
practitioner, the general practitioner in referring to a 
rheumatologist and the rheumatologist in assessing the 
patient following referral. The relationships between 
extents of delay and clinical and demographic variables 
were explored and data captured relating to sources of 
information, help and advice used by patients prior to GP 
consultation.
MethOds
A questionnaire based survey of consecutively presenting 
patients with a new onset of RA or unclassified inflam-
matory arthritis was undertaken in England and Scot-
land. Networks such as the Early Rheumatoid Arthritis 
Network24 and the National Institute for Health Research 
Clinical Research Network25 were used to identify 
rheumatology centres to participate in this study. RJS 
also promoted the study during abstract presentations at 
British Society for Rheumatology meetings.
Data were collected from rheumatology departments 
in 34 NHS Trusts. Rheumatology departments were 
secondary care based, although one rheumatology 
department (Sandwell and West Birmingham Hospitals) 
operated clinics in both hospital and community settings. 
Eligible patients were recruited on their first or second 
visit to the rheumatology department following a primary 
care referral (data were not collected on the numbers 
of patients whose data were collected at their first visit 
or at their second visit). Rheumatologists were asked to 
approach consecutively presenting patients who met the 
eligibility criteria. Eligible patients were newly referred 
adults (aged ≥18 years) with clinically apparent synovial 
swelling of one or more joints who had either a new onset 
of RA (according to 2010 American College of Rheuma-
tology/European League Against Rheumatism (ACR/
EULAR) criteria26 or unclassified arthritis (UA; defined 
as a failure to fulfil classification criteria for another 
inflammatory rheumatic disease). Patients with UA were 
recruited, as in many cases patients with UA at initial 
secondary care assessment progress to RA over time.27
Data were collected using two questionnaires (avail-
able from the corresponding author on request). First, 
following consent, the recruiting healthcare professional, 
with the patient present, completed a questionnaire that 
captured data on extents of delays between (1) symptom 
onset and seeing a healthcare professional (from herein 
referred to as ‘patient delay’, these data were gathered 
from the patient’s account by the recruiting healthcare 
professional); (2) seeing a general practitioner and being 
referred to a rheumatologist (from herein referred to 
as ‘general practitioner delay’, these data were gathered 
from the patient’s account by the recruiting healthcare 
professional); and (3) being referred to a rheumatologist 
and seeing a rheumatologist (from herein referred to as 
‘hospital delay’, these data were gathered from referral 
letters and hospital notes). Data were also gathered on 
(1) demographic variables including the patient’s age, 
gender, education, employment status and postcode; 
deprivation ranks were calculated from postcode data 
using Geoconvert 2010 which produced an Index of 
Multiple Deprivation (IMD) score;28 (2) clinical variables 
including the mode of symptom onset (palindromic 
(defined as intermittent symptoms) vs non-palindromic 
(defined as persistent symptoms)), rapidity of symptom 
onset (acute vs insidious; an acute onset was typically 
viewed as an onset of symptoms which came on rapidly 
over 24–48 hours), duration of morning stiffness, swollen 
and tender joint counts, Disease Activity Score 28 and 
fulfilment of 2010 ACR/EULAR criteria for classification 
of RA.26
In addition, via a separate questionnaire that patients 
completed by themselves, patients provided data on 
actions taken in relation to their symptoms prior to 
seeking help from primary care. The variables captured 
 o
n
 28 June 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-024361 on 4 March 2019. Downloaded from 
3Stack RJ, et al. BMJ Open 2019;9:e024361. doi:10.1136/bmjopen-2018-024361
Open access
were informed by previous qualitative research, including 
patient interviews and interviews with healthcare profes-
sionals. In addition, we had input from Patient Research 
Partners and the questions asked were validated and 
assessed for reliability.29
Patient and public involvement
Patient and public involvement was an important element 
of this study. Patient representatives from Sandwell and 
West Birmingham Hospitals NHS Trust were involved 
in the study design, advised on the content of patient 
facing materials including participant information sheets 
and consent forms and the content of questionnaires 
including questions related to actions taken by patients 
prior to consulting their GPs. Patients were members of 
the Project Management Group reviewing study recruit-
ment and supporting the group in developing approaches 
to ensure that recruitment proceeded to time and target.
Analysis
To ensure that the data met parametric assumptions, 
the distribution and levels of multicollinearity between 
variables were checked. Data on patient delays, general 
practitioner delays and hospital delays were not normally 
distributed; therefore, log values of these delay data were 
created to generate normally distributed variables.
For each of the outcomes patient delay, general prac-
titioner delay and hospital delay a general linear model 
was used with main effects and two-way interactions for 
the following explanatory variables: gender, ethnicity, 
IMD score, age, education, employment status, mode of 
onset, rapidity of onset, patient reported family history 
of RA and RA versus UA. For each outcome any two-way 
interactions which were not significant were removed in 
a backwards stepwise fashion, with the pairings with the 
highest p values being removed first. All main effects 
were retained, so that the final model for each outcome 
included all ten explanatory variables and any significant 
two-way interactions (p<0.01). All significant main effects 
and interactions are reported in the Results section.
results
Participant characteristics
Data were collected from 856 patients between 2011 and 
2014. Patients were withdrawn from the study due to 
incomplete data (21 cases) and ineligibility (13 cases in 
whom there was no clinical synovitis reported at recruit-
ment). Data were thus analysed from 822 patients of 
whom 68.5% were female with a mean age of 55 years. 
Characteristics of patients are presented in table 1.
Intervals between symptom onset and first rheumatology 
consultation
Overall, the median time between symptom onset and 
seeing a rheumatologist was 27.2 weeks (IQR 14.1–66 
weeks); only 20% of patients were seen within the first 
3 months following symptom onset. The median patient 
delay was 5.4 weeks (IQR 1.4–26.3 weeks). The median 
general practitioner delay was 6.9 weeks (IQR 2.3–20.3 
weeks) with patients making a mean of 4 GP visits before 
being referred. The median hospital delay was 4.7 weeks 
(IQR 2.9–7.5 weeks).
Palindromic onset is defined as intermittent symp-
toms, while non-palindromic is defined as persistent 
symptoms. Acute onset is defined as symptoms which 
came on rapidly over 24–48 hours, while insidious onset 
is defined as symptoms which developed slowly over an 
extended period of time. Patients with a palindromic 
symptom onset had a significantly longer patient delay 
than those with a non-palindromic onset (9.3 weeks (IQR 
2–43 weeks) vs 4.3 weeks (IQR 1–17 weeks); p<0.001, 
t-test). Furthermore, those with an acute symptom onset 
had significantly shorter patient delays than those with an 
insidious symptoms onset (2.4 weeks (IQR 1–6.6 weeks) vs 
11.1 weeks (IQR 4–44 weeks); p<0.001, t-test).
Resources used before seeking help from primary care
Patients reported taking a range of actions in relation to 
their symptoms before seeking help from their GP and 
in some cases these actions were associated with longer 
delays in GP consultation (see table 2). Most often, 
patients reported purchasing tablets from ‘the chemist’, 
although only a small proportion actually reported 
Table 1 Demographic and disease-related characteristics 
of patients
Female 68.5% (563)
Age, years 57 (45–67)
Diagnosis of RA 73% (603)
Ethnicity
  Black British 6.0% (49)
  South Asian 7.7% (63)
  White British 84.9% (698)
  Other 1.5% (12)
Self-reported family history of RA 34.9% (287)
Palindromic onset 42.8% (352)
Acute onset 35.9% (295)
Duration of morning stiffness, minutes 60 (10–120)
DAS28 4.88 (3.98–5.80)
Health Assessment Questionnaire (HAQ) 1.13 (0.50–1.73)
Tender joint count 9 (4–18)
Swollen joint count 5 (2–10)
Data are presented as either percentage (number) or median (IQR) 
as appropriate.
Tender joint count is out of 42 joints (10 proximal interphalyngeal 
(PIP), 10   metacarpophalyngeal (MCP), two wrist, two elbow, two 
shoulder, two hip, two knee, two ankle, 10 MTP). Swollen joint 
count is out of 40 joints (10 PIP, 10 MCP, two wrist, two elbow, two 
shoulder, two knee, two ankle, 10 MTP).
DAS28, Disease Activity Score 28; HAQ, Health Assessment 
Questionnaire; MCP, metacarpophalyngeal; PIP, proximal 
interphalyngeal; RA, rheumatoid arthritis.
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speaking to a pharmacist. Other actions reported by 
patients included applying heat or cold packs to joints or 
buying joint supports.
Thirty-seven per cent of patients reported looking on 
the internet (eg, visiting the NHS direct website, Arthritis 
Research UK website and searching for information using 
search engines such as Google). Patients also reported 
seeking support via a telephone helpline; 5.7% described 
calling the NHS direct helpline or another telephone 
health advice service. 3.7% sought help in the workplace 
(eg, from an occupational nurse), 2% of patients went 
directly to the accident and emergency department and 
1% attended an NHS walk-in centre.
Multivariate analysis: patient delay
The interaction model showed main effects for mode of 
onset (palindromic vs non-palindromic; F=26.65, p<0.01) 
and rapidity of onset (acute vs insidious; F=65.36, p<0.01). 
An interaction was found between palindromic onset and 
gender (F=45.658, p<0.01); men with a palindromic onset 
waited significantly longer before seeking help.
Multivariate analysis: general practitioner delay
A main effect was found for ethnicity (F=6.26, p<0.01). 
Significant differences in general practitioner delay were 
found between white British and South Asian patients (6.2 
weeks (IQR 2–18.6) vs 22 weeks (IQR 6.5–39.8); p<0.001) 
and between white British and black British patients 
(6.2 weeks (IQR 2–18.6) vs 11.1 weeks (IQR 4.3–21.7); 
p<0.001). No significant difference was found between 
South Asian and black British patients (p=1.000).
A main effect was also found for family history (F=5.89, 
p<0.01); the median general practitioner delay for those 
with a self-reported family history of RA was 9 weeks (IQR 
2.4–25.7), while general practitioner delay for those with 
no family history was 6.3 weeks (IQR 2.3–19). Interactions 
at a statistically significant level (<0.01) were not found.
Multivariate analysis: hospital delay
The original model included main effects and two-way 
interactions for the following explanatory variables: 
gender, ethnicity, IMD score, age, education, employment 
status, mode of onset, rapidity of onset, family onset and 
RA versus UA. None of the main effects or interactions 
(when removed backwards) were significant in predicting 
the delay between referral and being seen in secondary 
care.
dIsCussIOn
International guidelines recommend that the treatment 
of RA should begin as soon as possible after the onset of 
symptoms, ideally aiming to capture patients within the 
first 3 months following symptom onset. However, this 
large UK study of delays in access to care for patients with 
RA found that the median patient delay in seeking help 
at the onset of symptoms was 5.4 weeks, while the median 
delay between seeing a healthcare professional and being 
referred was 6.9 weeks. Our study highlights that only 20% 
of patients were seen within the first 3 months of symptom 
onset. This appears to be lower than the rate reported in 
other European countries, for example, a recent study in 
Austria reported that 38% of patients were seen within the 
first 3 months.30 The present study also found an average 
delay of 4.7 weeks from referral until the patient was seen 
by a rheumatologist, similar to figures reported in the 
NAO report.3 Unlike our previous study conducted at a 
single centre in the UK where patient delay accounted for 
the largest element of delay,13 we found that GP delay was 
the largest contributor to overall delay; patient delay was 
less than we had previously reported in our single centre 
study.
This research highlights that delays in primary care 
are long, and a major contributor to overall delays 
Table 2 Actions taken by patients with inflammatory arthritis before seeking help from their GP with comparison made for 
patient delay between those who did and did not undertake this action using independent t-tests
Actions taken before seeking help 
from GP
% (number) of 
participants undertaking 
this action
Median (IQR) patient 
delay in weeks for those 
undertaking this action
Median (IQR) patient delay 
in weeks for those not 
undertaking this action P value*
Bought tablets from the chemist 51.1% (273 out of 534) 6.9 (2–30.7) 4.7 (1.4–23) 0.036
Used an ice or heat pack on joint 47.8% (254 out of 531) 7.6 (2–30.3) 4.9 (2–26.1) 0.045
Took baths 47.4% (251 out of 529) 6.3 (2–30.4) 5.6 (2–26.1) 0.473
Bought joint supports (splints, tubi-
grips, etc)
37.4% (198 out of 529) 4.4 (2.1–18.6) 5.1 (2–26.9) 0.362
Used alternative therapies 25.2% (134 out of 531) 8.3 (2–42.1) 5.3 (2–26.3) 0.020
Bought products from a health shop 19.0% (101 out of 532) 5.9 (2–36.3) 5.9 (2–26) 0.182
Modified diet 14.4% (76 out of 529) 6 (2.1–35.3) 6.1 (2–26.3) 0.183
Used prayer or sought spiritual 
guidance
8.4% (45 out of 534) 4.4 (2.1–18.6) 6.3 (2–26.9) 0.941
Spoke to a pharmacist 7.9% (41 out of 521) 5.9 (2–38.1) 5.9 (2–26.3) 0.544
*P value for comparison of those who did and did not undertake this action.
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between symptom onset and the first rheumatology 
visit. General practitioners are faced with a number of 
barriers to identifying patients with newly presenting 
RA including the often non-specific nature of symptoms 
at the earliest stages of RA.18 Research is under way to 
define symptom complexes most predictive of RA devel-
opment in patients with newly presenting musculoskel-
etal symptoms. For example, a questionnaire has been 
developed and validated to capture such symptoms in 
patients presenting with joint symptoms which by history 
are suggestive of an underlying inflammatory cause31 and 
data are currently being collected from such patients in 
secondary care based longitudinal observational cohort 
studies to identify symptoms that may predict RA develop-
ment. Furthermore an assessment of primary care data-
bases has identified a range of symptoms including hand 
related joint symptoms, morning stiffness and carpal 
tunnel syndrome type symptoms as being ones with which 
patients frequently present to the GP prior to the point 
at which the GP refers the patient to a rheumatologist or 
records a diagnosis of RA.32 It is likely that a combination 
of education, and evidence based referral algorithms, will 
be needed to ensure that suspected cases are referred 
early. For example, in Fife, Scotland, GPs did not have 
access to rheumatoid factor testing during the course of 
our study, and used guidelines with pictorial representa-
tions to help identify early synovitis (H Harris, personal 
communication, 2015). Fife was a participating centre in 
this study, and was found to have the shortest GP referral 
time of all centres surveyed. Furthermore, facilitating 
access to secondary care, for example, through the estab-
lishment of rapid assessment clinics whose main aim is to 
identify whether the patient does or does not have syno-
vitis has been shown to significantly reduce delays in the 
assessment of patients.33 A limitation of our research is 
that the study was not able to assess regional differences 
across NHS Trusts. A study comparing delays and referral 
patterns between hospitals with local policies and prac-
tices which may influence the time between onset and 
first consultation would be useful and an international 
study would be particularly helpful. In addition, this study 
did not examine the distances between patients’ homes 
and their local GP surgeries, and hospitals and so we were 
unable to assess whether physical distance between the 
patient’s home and the GP surgery or hospital influenced 
delay.
A number of factors were found to influence GP delay 
including ethnicity. Some studies in the field of oncology 
have also found that people from ethnic minority back-
grounds face longer GP delays.34 35 In the context of RA, 
it is possible that the early symptomatology of patients 
from ethnic minority backgrounds is different from, and 
less typical of RA than that of, patients of white British 
background, thus making recognition more challenging 
for GPs. Data certainly exist that the clinical pheno-
type of established RA differs in patients of South Asian 
origin compared with patients of white British origin,36 
though data relating the clinical presentations of RA in 
these groups are lacking. Furthermore, it is unclear why 
a self-reported family history of RA would be associated 
with longer delays although it is important to recognise 
that GPs may not have elicited this information from the 
patient. Qualitative approaches may be helpful to address 
some of these issues in the future.
Previous qualitative studies and a meta-synthesis have 
identified barriers to help seeking at the onset of RA.37–43 
The present study identifies that before seeking formal 
medical attention, people experiencing the early symp-
toms of RA seek information and help from a number 
of alternative sources and often self-medicate. We iden-
tified that buying tablets from a pharmacy and using 
heat or ice on joints were significantly associated with 
longer patient delays. This finding highlights that some 
self-management behaviours, particularly those linked to 
accessing pharmacy services can negatively impact on the 
time it takes to seek help; this needs further exploration. 
Factors previously suggested to be associated with delays 
in GP consultation included an insidious onset of mild 
symptoms and a lack of knowledge about RA, personal 
susceptibility to RA and the availability of treatments to 
slow disease progression. In our national sample 64.1% 
of people describe an insidious onset of RA, and 42.8% 
describe a palindromic onset of RA. Therefore, a large 
proportion of patients surveyed experienced a slow and/
or intermittent onset of their inflammatory joint symp-
toms. Our quantitative data are consistent with results 
from qualitative studies, demonstrating that the mode 
and rapidity of onset of symptoms is significantly associ-
ated with patient delays.
This study has a number of limitations. First, the 
interval between first consultation with a rheumatologist 
and initiation of DMARD treatment was not measured. 
Any additional delay in commencing DMARD treatment 
will negatively impact the patient and variables associ-
ated with delays at this level should be assessed in future 
studies. Second, during the course of this study, a number 
of guidelines related to RA management were published 
which may have influenced practice, and patterns of 
referral. We were not able to explore the relationships 
between the availability/local adoption of guidelines and 
delays in the assessment of patients. Future investigation 
should assess the impact of policy changes on patterns of 
help-seeking, referral and assessment. Third, the rheuma-
tology centres participating in this study were self-selecting, 
therefore, there may be biases in the characteristics of the 
rheumatology centres which participated in this study. 
For example, the participating rheumatology units may 
have had a particular interest in early arthritis. Only a 
study which recruited consecutive patients from all rheu-
matology units across the UK would be able to provide a 
truly national picture. Fourth, while we were able to docu-
ment the length of delay at a primary care level there were 
important variables which may have influenced this delay 
which we did not record and so were unable to explore. 
For example, it would have been helpful to have access 
to results of tests performed in primary care to assess 
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whether levels of inflammatory markers or RA related 
autoantibodies measured in primary care influenced the 
rapidity of referral from primary care. Indeed a recent 
quantitative survey of GPs’ anticipated actions in primary 
care when dealing with patients with suspected RA suggest 
that results of these tests may influence GP behaviours.44 
Future research should address this. Similarly, a number 
of secondary care related variables may have influenced 
the extent of secondary care delay including the number 
of rheumatologists at each Trust, whether a dedicated 
early arthritis clinic was in place and approaches taken 
to the triage of referrals. Data relating to these variables 
were not collected though future work addressing issues 
of delay should address these important issues. Fifth, data 
relating to the dates of onset of symptoms and initial GP 
consultation were gathered from patients’ histories, and 
therefore relied on patient recollection with a possible 
associated error. However, a previous study addressing 
delays in the assessment of patients with RA, compared 
patient accounts of their journeys to first rheumatology 
consultation against medical records and highlighted the 
accuracy of patient recollection in relation to dates found 
to be documented in primary care records.20 This, to some 
extent, validates our approach of using patient memory to 
define the dates of symptom onset and initial GP presen-
tation. An alternative approach would be a longitudinal 
observational study in the general population to track the 
development of symptoms and the relationship between 
that and GP consultation, GP referral and secondary care 
assessment. A challenge with this approach is the low inci-
dence of RA and thus the requirement for a very large 
sample size. One could potentially enrich the population 
for RA risk by, for example, following individuals who are 
at increased risk of RA (eg, the first degree relatives of 
patients with RA). However, one of the challenges with 
this strategy is that simply being involved in such a study 
may influence subsequent patient and GP behaviour.
While delays in primary care are the largest contributor 
to overall delay, patient delay and hospital delay repre-
sent important components. This study found that the 
nature of symptom onset influenced how quickly patients 
with RA sought help, suggesting that those with an acute 
onset of persistent symptoms seek help faster than those 
with insidious and palindromic onsets. Interventions 
to encourage rapid help seeking should consider high-
lighting the frequently insidious onset of RA to members 
of the public stressing that help should be sought even 
when symptoms are mild. However, even those with 
a rapid onset of persistent symptoms often delayed for 
prolonged periods before seeking help. We have previ-
ously shown that members of the public view musculo-
skeletal symptoms, even those with clear inflammatory 
features, as less worrisome and less requiring rapid assess-
ment as compared with symptoms of other common 
diseases such as ischaemic type chest pain or bowel 
disturbance with associated rectal blood loss.45 Enhanced 
public education to highlight the significance of inflam-
matory type musculoskeletal symptoms is thus likely to be 
needed. Interventions at multiple levels, including at the 
levels of the public, the services which members of the 
public consult after the onset of symptoms (eg, pharma-
cies), primary care and secondary care will be needed to 
reduce overall delays in access to appropriate specialists.
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